Integra LifeSciences
IART
234 hedge funds and large institutions have $2.75B invested in Integra LifeSciences in 2016 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 89 increasing their positions, 82 reducing their positions, and 14 closing their positions.
3,257% more call options, than puts
Call options by funds: $8.26M | Put options by funds: $246K
193% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 14
11% more funds holding
Funds holding: 210 → 234 (+24)
9% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 82
3% more capital invested
Capital invested by funds: $2.67B → $2.75B (+$77.5M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$64.6M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$33.8M |
| 3 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
+$25.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.3M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$27.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7M |
| 3 |
SAM
Silvercrest Asset Management
New York
|
-$18.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$16.3M |
| 5 |
SCM
Sandler Capital Management
New York
|
-$12.7M |
IART Hedge Fund Activity: Q3 2016 in Review
234 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2016, worth a combined $2.75B — up 2.9% from $2.67B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IART positions and 14 closed out — a net gain of 27 holders — while 89 added to existing stakes and 82 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $64.6M. The largest seller was Vaughan Nelson Investment Management, cutting an estimated $27.1M.
- 234 institutional investors held Integra LifeSciences (IART) as of Q3 2016, up from 210 in Q2 2016.
- Funds reported $2.75B of Integra LifeSciences stock for Q3 2016, up 2.9% quarter-over-quarter.
- 41 funds opened new Integra LifeSciences positions in Q3 2016 and 14 closed out, a net change of +27 holders.
- The largest Integra LifeSciences buyer in Q3 2016 was Victory Capital Management, an estimated $64.6M added.
- The largest Integra LifeSciences seller in Q3 2016 was Vaughan Nelson Investment Management, an estimated $27.1M sold.
Based on aggregated 13F filings for Q3 2016.